Junshi Biosciences Shares Soar as Unit Taps Ex-FDA Official to Fire Up Global Strategy
Lin Zhiyin
DATE:  Aug 10 2020
/ SOURCE:  Yicai
Junshi Biosciences Shares Soar as Unit Taps Ex-FDA Official to Fire Up Global Strategy Junshi Biosciences Shares Soar as Unit Taps Ex-FDA Official to Fire Up Global Strategy

(Yicai Global) Aug. 10 -- Shares of Junshi Biosciences climbed after a unit appointed a veteran of the US Food and Drug Administration as its new chief medical officer to push forward its globalization strategy.This is the third time that the Chinese drugmaker has recruited a former FDA technical officer.

Junshi Biosciences’ stock price [SHA: 688180] closed 4.6 percent higher today at CNY121.3 (USD17.40), after gaining as much as 6 percent earlier in trading.

As CMO of TopAlliance Biosciences, Patricia Keegan will lead and supervise clinical development programs and be in charge of strategy, directing and carrying out the firm’s clinical development plans. She will also take part in drafting the overall strategy. The wholly owned unit also named Dr. Keegan as a senior vice president, Shanghai-based Junshi Biosciences said in a statement released today.

Keegan has decades of experience as a board-certified medical oncologist, clinical researcher and regulatory authority. During 30 years at the FDA, she held a number of positions, including oncology medical officer, deputy director of clinical trials design and analysis, and director of oncology products. Her last post was acting associate director of the FDA’s Medical Policy Oncology Center for Excellence.

China’s drugmakersare competing with one another for top talent from the US’ food and drug watchdog because the American market is crucial to their global expansion plans. WuXi Biologics, Tasly and Luye Pharma Group have also scouted ex-FDA officials in recent years.

Keegan will join two other former FDA officials at Junshi Biologics. Li Ning, previously an FDA branch chief, joined in January 2018 and is now chief executive. Last August, Wang Gang, a former FDA chief scientist, also came on board as senior vice president for industry affairs and chief quality officer responsible for production quality and related work.

Editors: Xu Wei, Peter Thomas

Follow Yicai Global on
Keywords:   Shanghai Junshi Biosciences,FDA,Management